Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
Ovariectomy
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "Ovariectomy" in MCE Product Catalog:
22
22 Publications Verification
Synonyms: β-Estradiol 3-benzoate; 17β-Estradiol 3-benzoate
Category:
Target:
1
1 Cited Publications
Cat. No.: HY-W012980
CAS No.: 503-74-2
1
1 Cited Publications
Cat. No.: HY-N0608
CAS No.: 171485-39-5
Cat. No.: HY-N9331
CAS No.: 163046-73-9
Synonyms: Cimicidanol-3-O-β-d-xyloside
Category:
Triterpenes Terpenoids Ranunculaceae Metabolic Disease Plants Cimicifuga foetida Linn. Disease Research Fields
Target:
Cat. No.: HY-W012980R
CAS No.: 503-74-2
Cat. No.: HY-123370
CAS No.: 174185-16-1
Target:
Research Areas:
FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .
Synonyms: β-Estradiol 3-benzoate (Standard); 17β-Estradiol 3-benzoate (Standard)
Research Areas:
Estradiol benzoate (Standard) is the analytical standard of Estradiol benzoate. This product is intended for research and analytical applications. Estradiol benzoate (β-Estradiol 3-benzoate) is a HBx protein inhibitor and inhibits androgen and hepatitis B virus (HBV) transcription, replication. Estradiol benzoate shows antifertility effects, anti- Toxoplasma gondii activity and can improve memory behavior of Ovariectomy (Ovx) female mice .
Cat. No.: HY-106256
CAS No.: 214140-47-3
Target:
Research Areas:
HMR-3339 is a new selective estrogen receptor modulator. HMR-3339 reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine. HMR-3339 corrects bone alterations induced by ovariectomy .
Cat. No.: HY-175669
Target:
Research Areas:
ANO1-IN-5 is an orally active ANO1 inhibitor with an IC50 of 4.57 μM. J ANO1-IN-5 demonstrates 118-, 642-, and 10000-fold selectivity over α1A-,α1B-, andα1D-AR, respectively. ANO1-IN-5 exhibits significant inhibitory effects on osteoclast differentiation and function. ANO1-IN-5 can used for the study of osteoporosis .
Cat. No.: HY-164532
CAS No.: 265646-94-4
Target:
Research Areas:
NS3736 is an orally effective chloride channel inhibitor that can be used for the research of osteoporosis. NS3736 targets the CIC-7 channel in osteocytes, blocks osteoclast acidification and resorption in vitro, with IC50=30 μM. In a rat model of ovariectomy-induced osteoporosis, NS3736 can enhance bone strength and bone density .
Cat. No.: HY-14360
CAS No.: 919109-76-5
Target:
Research Areas:
MK 1256 is a highly selective and orally active inhibitor of tissue protease K (Cat K) with an IC50 of 0.62 nM. MK 1256 shows extremely high selectivity towards other tissue proteases (all > 1100 times), with only a slightly lower selectivity for tissue protease F (Cat F) (110 times). MK 1256 exhibits strong anti-bone resorption activity in the osteoporosis model of rhesus monkeys with ovariectomy. MK 1256 can be used for research on osteoporosis .
Cat. No.: HY-111248
CAS No.: 871113-99-4
Research Areas:
ABD-295, a biphenylsulfide derivative, is an antiresorptive agent, osteoclast inhibitor. ABD-295 has potent inhibitory effects on osteoclastic bone resorption in vitro. ABD-295 prevents ovariectomy-induced bone loss in vivo [1] .
Cat. No.: HY-149358
CAS No.: 2854331-14-7
Target:
Research Areas:
NK3R-IN-1 (compound 16x), a imidazolepiperazine derivative, is an orally active Neurokinin Receptor NK3R inhibitor. NK3R-IN-1 decreases blood luteinizing hormone levels in ovariectomy (OVX) model .
Cat. No.: HY-N0608S
Cat. No.: HY-W185542
CAS No.: 1043110-13-9
Research Areas:
E09241 is an orally active osteoclastogenesis inhibitor. E09241 reduces the RANKL-induced expression of NFATc1 and MMP-9 by activating Wnt/β-catenin. E09241 increases the OPG/RANKL ratio by upregulating OPG expression, inhibits bone resorption, promotes bone formation and prevents ovariectomy-related bone loss. E09241 can be used in the research of osteoporosis .
Cat. No.: HY-118668
CAS No.: 1117772-52-7
ABD-350 is an antiresorptive agent that inhibits osteoclast activity without affecting osteoblast activity and preventing ovariectomy-induced bone loss. ABD-350 inhibits NF-κB ligand-induced inhibitor of NF-κB phosphorylation, leading to osteoclast apoptosis, but has no inhibitory effect on osteoblast function, effectively preventing bone loss in ovariectomized mice, and does not inhibit parathyroid hormone-induced bone formation.
Cat. No.: HY-180801
CAS No.: 2419580-01-9
Research Areas:
E8431 is a DCSTAMP antagonist. DCSTAMP is a key fusion protein that coordinates cell-cell fusion during osteoclastogenesis. E8431 inhibits the cytoskeleton reorganization mediated by the RAP1B-RAC1 signaling pathway. E8431 has the ability to inhibit pre-fusion of osteoclasts and, while inhibiting bone resorption, stimulates the secretion of PDGFBB, thereby stimulating the process of bone and blood vessel formation. E8431 effectively reduces bone loss in a mouse model caused by ovariectomy. E8431 can be used for the study of osteoporosis .
Cat. No.: HY-178355
Target:
Research Areas:
Anti-osteoporosis agent-12 (Compound 18) is an orally active pyrazole-fused betulinic acid derivative with potent anti-osteoporosis activity. Anti-osteoporosis agent-12 exhibits a strong inhibitory effect on RANKL-induced osteoclastogenesis in RAW264.7 cells, with an IC50 of 7.96 nM. Anti-osteoporosis agent-12 can dose-dependently improve key micro-CT parameters of bone, reduce the level of serum bone resorption marker (CTx), and effectively prevent ovariectomy-induced bone loss. Anti-osteoporosis agent can be used for the study of osteoporosis .
Cat. No.: HY-182757
CAS No.: 2812381-74-9
Research Areas:
Y1693 is an orally active RANKL inhibitor with a Kd of 5.03 μM for hRANKL. Y1693 inhibits the activation of the downstream c-fos/NFATc1 signaling pathway by blocking its interaction with RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation and bone resorptive activity, while downregulating the mRNA and protein expressions of TRAP, cathepsin K, c-fos and NFATc1. Y1693 shows no obvious cytotoxicity to bone marrow-derived macrophages and osteoclast precursor cells, and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research related to osteoporosis and periodontal diseases .
Cat. No.: HY-123500
CAS No.: 134520-88-0
Target:
Research Areas:
CGP-45688 is an orally active non-steroidal aromatase inhibitor with an ED50 of 30-100 μg/kg. CGP-45688 can reduce the level of estrogen in the body, thereby inhibiting the growth of estrogen-dependent tumors. CGP-45688 inhibits the growth of estrogen-dependent breast tumors in rat models. CGP-45688 disrupts the ovarian cycle and inhibits the weight of the uterus. CGP-45688 can be used for the study of breast cancer .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
